High-Concentration Radiopharmaceutical Composition With Dual Stabilizers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiopharmaceutical drugs with GRP receptor peptide antagonists suffer from radiolytic degradation during manufacturing and storage, leading to instability and limited shelf-life, necessitating on-site production and administration, which complicates patient convenience and stability.
Innovation Solution
A highly concentrated pharmaceutical composition is developed, comprising a radionuclide complex with a GRP receptor peptide antagonist, stabilizers like gentisic acid and ascorbic acid, and optionally a surfactant, ensuring chemical and radiochemical stability even at ambient temperatures, allowing commercial-scale production and ready-to-use solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If radiopharmaceutical composition is stored at ambient temperature for extended periods, then convenience and shelf-life are improved, but radiolytic degradation increases leading to instability
Solution Approach 1:
The patent introduces stabilizing agents (ascorbic acid, gentisic acid, methionine, histidine) as intermediary substances that mediate between the radiopharmaceutical composition and radiolytic degradation. These stabilizers act as sacrificial agents that preferentially undergo oxidation or radical formation, protecting the active radiopharmaceutical components from degradation and enabling extended storage at ambient temperatures while maintaining radiochemical stability.
Solution Approach 2:
The patent creates a protective chemical environment by formulating the radiopharmaceutical composition with stabilizing agents that establish an inert-like protective atmosphere against radiolytic processes. The stabilizers form protective complexes or antioxidant shields that prevent oxygen and radical-mediated degradation, effectively creating a protected environment that allows ambient temperature storage without compromising stability.
2Reliability
If radiopharmaceutical composition is diluted to reduce radiolysis, then stability is improved, but concentration and dosing efficiency deteriorate
Solution Approach 1:
The stabilizing agents serve as intermediaries that enable high concentration storage without radiolysis. By intercepting and neutralizing radiolytic radicals and oxidation processes, the stabilizers allow the radiopharmaceutical to be stored at high concentrations (e.g., 1-10 mCi/mL) while maintaining stability, eliminating the need for dilution.
Solution Approach 2:
The patent employs sacrificial stabilizing agents that are consumed during storage to protect the valuable radiopharmaceutical composition. These stabilizers (ascorbic acid, gentisic acid, etc.) act as disposable protective elements that undergo degradation themselves but prevent degradation of the active components, allowing high concentration storage without compromising the integrity of the radiopharmaceutical.
3Reliability
If on-site production is implemented to ensure stability, then radiochemical purity is maintained, but patient convenience and operational complexity worsen
Solution Approach 1:
The patent applies preliminary action by pre-formulating the radiopharmaceutical composition with stabilizing agents and quality control measures during manufacturing. The composition is pre-stabilized against radiolytic degradation through the inclusion of antioxidants and protective agents, allowing it to be stored and transported to patient locations without requiring on-site production. This maintains radiochemical purity while improving patient convenience.
Solution Approach 2:
The stabilizing agents act as intermediaries that enable the radiopharmaceutical to maintain its integrity during transport and storage. These agents mediate the protection of the composition from degradation throughout the supply chain, eliminating the need for on-site preparation and allowing centralized manufacturing with distributed administration to patients.
4Quantity of substance
If high concentration composition is used for therapeutic efficacy, then treatment effectiveness is improved, but radiolytic degradation accelerates reducing stability
Solution Approach 1:
The stabilizing agents function as intermediaries that enable high concentration formulation without accelerating radiolytic degradation. By preferentially reacting with radiolytic radicals and providing antioxidant protection, these stabilizers allow the radiopharmaceutical to be stored at high concentrations (1-10 mCi/mL) while maintaining radiochemical stability, thus achieving both high concentration and high stability simultaneously.
Solution Approach 2:
The patent creates a composite radiopharmaceutical formulation by combining the radiopharmaceutical active ingredients with stabilizing agents (ascorbic acid, gentisic acid, methionine, histidine) and other excipients in a synergistic formulation. This composite system leverages the protective properties of the stabilizers to enable high concentration storage without compromising stability, achieving both therapeutic efficacy and formulation stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains high radiochemical purity and stability for up to 72 hours, enabling convenient, stable, and tolerable administration with reduced volumes, suitable for commercial use and therapeutic applications.
Implementation Method 1
stabilizer against radiolytic degradation
Implementation Method 2
stabilizers like gentisic acid and ascorbic acid
Implementation Method 3
a complex formed by a radionuclide, and a GRP receptor peptide antagonist binding moiety linked to a chelating agent
Implementation Method 4
optionally a surfactant
Data Source
AI summary
The present disclosure relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.